NEW DELHI, May 25 -- India has issued an urgent public health notice asking patients, consumers and healthcare professionals across the country to closely monitor and report any adverse reaction associated with the use of semaglutide and other popular diabetes and weight-loss medications, according to two officials and a document seen by Mint.

The Indian Pharmacopoeia Commission (IPC), the health and family welfare ministry's apex body responsible for setting drug standards, issued a public notice on 14 May calling for monitoring the safety of glucagon-like peptide-1 (GLP-1) drugs including the blockbuster semaglutide and dulaglutide, liraglutide and tirzepatide.

Given their rapid clinical adoption, regulatory authorities including IPC,...